Zevra Therapeutics, Inc. (ZVRA) Cash Flow Statement
Zevra Therapeutics, Inc. (ZVRA) generated $33.4M of operating cash flow over the twelve months to 2026-06-30, spent $775000 on capital expenditure and had free cash flow of $32.6M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ZVRAZevra Therapeutics, Inc.Follow ZVRA — free
—
Price chart with a free account
- Market cap
- 582.6M
- P/E TTM
- 10.7
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -23.7 | -1.9 | 10.4 | -18.7 | -33.5 | -69.7 | -1.6 | 33.4 | |
| Capital expenditure | 0.0 | 0.0 | 0.1 | 0.1 | 0.3 | 0.0 | 0.8 | -0.8 | |
| Free cash flow | -23.8 | -2.0 | 10.3 | -18.8 | -33.8 | -69.7 | -2.4 | 32.6 | |
| Share repurchases | — | — | 2.8 | 4.7 | 3.4 | 0.0 | — | — | |
| Stock-based compensation | 4.4 | 2.5 | 2.4 | 4.3 | 6.0 | 14.9 | 12.6 | — |
USD millions · SEC XBRL
Zevra Therapeutics, Inc. — questions
- What is Zevra Therapeutics, Inc.'s operating cash flow?
- $33.4M over the twelve months to 2026-06-30.
- How much does Zevra Therapeutics, Inc. spend on capital expenditure?
- $775000 over the twelve months to 2026-06-30.
- What is Zevra Therapeutics, Inc.'s free cash flow?
- $32.6M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Zevra Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.